Citations

Clear

572 citation(s) found for "Silva, P".

Multilocus Sequence Typing Reveals New Insights into the Population Structure and Genetic Diversity of Lactococcus spp. from Brazilian Fish
Tavares, Guilherme Campos , Carneiro, Sarah Portes , Barbanti, Angelo Carlo Chaparro , Rosário, Angélica Emanuely Costa do , Matos, Helena Caldeira , Maia, Cynthia Rafaela Monteiro da Silva, Costa, Henrique Lopes , Nogueira, Luiz Fagner Ferreira , Rosa, Júlio César Câmara , Pereira, Felipe Luiz, Pilarski, Fabiana , Gallani, Sílvia Umeda , Leal, Carlos Augusto Gomes , Figueiredo, Henrique César Pereira , Pereira, Felipe Luiz , Nogueira, Luiz Fagner Ferreira , Rosa, Júlio César Câmara , Pereira, Felipe Luiz , Pilarski, Fabiana , Gallani, Silvia Umeda , Leal, Carlos Augusto Gomes , Figueiredo, Henrique César Pereira , Egger, Renata Catão , Soto, Esteban

Mayo Clinic

Microorganisms | May 18, 2026 | Volume: 14 | Issue: 5 | Pages: 1131

10.3390/microorganisms14051131 | PMID 42197516 Get It

Lactococcosis has emerged as an economically and ecologically significant disease in aquatic animals worldwide. This study employed multilocus sequence typing (MLST) to investigate the genetic diversity of Lactococcus spp. strains from Brazilian fish species and evaluate their phylogenetic relationships with global isolates to elucidate potential epidemiological connections involving multiple host species and distinct geographic regions. A total of 55 isolates from different laboratories had their DNA extracted, followed by the amplification and sequencing of the internal fragments of seven housekeeping genes (als, atpA, tuf, gapC, gyrB, rpoC and galP). Sequence types (STs) and clonal complexes (CCs) were defined. An unrooted neighbor-joining phylogenetic tree was generated using allele profiles from this study and those previously reported from other aquatic animal species. The isolates comprised 29 STs (11 previously reported, 18 novel ones), which were grouped into species-specific CCs: CC5 (L. formosensis); CC4, CC17, CC62 (L. garvieae); CC24, CC29, CC97 (L. petauri). Considerable genetic divergence was observed, with L. formosensis and L. garvieae forming heterogeneous populations, while L. petauri was more homogeneous. These findings describe the MLST structure of the sampled isolates and should be interpreted as hypothesis-generating rather than population-level estimates of genotype prevalence. Phylogenetics confirmed groupings within the CCs and revealed additional phylogenetic clustering patterns. In conclusion, the Brazilian Lactococcus spp. strains analyzed in this study constitute a genetically diverse population based on their STs. MLST and phylogenetic analysis demonstrated genetic relatedness between the L. garvieae and L. formosensis isolates from this study and those from other aquatic animal species. In contrast, all the STs identified for L. petauri in this study were unrelated to the MLST lineages responsible for outbreaks in Brazilian Nile tilapia (Oreochromis niloticus) and North American rainbow trout (Oncorhynchus mykiss). This suggests that piscine L. petauri populations in the Americas evolved from distinct ancestral origins.
Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology
Nguyễn, Long Thành , Hoyek, Celine , Magliano, Carlos, Mano, Max S., Prabhash, Kumar, Moraes, Fabio Ynoe , Loon, Katherine Van , Sonbol, Mohamad Bassam , Van Loon, Katherine , Kapoor, Akhil , Magliano, Carlos Alberto da Silva , Mano, Max S.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 11, 2026 | Volume: 46 | Issue: 3 | Pages: No page available

10.1200/edbk-26-528840 | PMID 42114030 Get It

By 2045, more than three quarters of global cancer deaths are projected to occur in low- and middle-income countries (LMICs); however, the global availability of cancer care remains constrained by high costs and inequitable access. Value-based frameworks that integrate clinical benefit with affordability, feasibility, and equity are essential to better guide research prioritization, resource allocation, and regulatory policies in LMICs. A key component of a value-based approach is the generation of high-quality, locally relevant data to support evidence-based implementation of cancer prevention and control strategies. Herein, we provide three contemporary examples from JCO Global Oncology which demonstrate how economic evaluation in cancer research can address locally relevant, health system–specific questions.
Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study
Cari, Vania , Pérez, María Ignacia , Tellez, Ignacio , Idalsoaga, Francisco, Valsan, Arun , Nair, Gowripriya , Soni, Kriti , Rhoads, S. Fisher , Arnold, Jorge , Ayala-Valverde, Maria, Ramirez-Cadiz, Carolina, Jalal, Prasun K., Ibrahim, Mohamad Ali , Elfeki, Mohamed A., Simian, Daniela , Córdova, Jacqueline, Higuera‐de‐la‐Tijera, Fátima , Silva, Rita, Rocha, Cristina Melo , Araujo, Roberta C., Fontani, Guilherme Massote, Pereira, Gustavo Henrique, Bessone, Fernando, Tanno, Mario, Kisch, Ayelen, Mendizabal, Manual, Marciano, Sebastian, Gomez-Perdiguero, Gonzalo, Montes, Pedro, Salazar, Patricia Guerra, Ramos, Geraldine, Chacko, Kristina R., Skladaný, Lubomir, Maiwall, Rakhi, SIMONETTO, DOUGLAS, Sanyal, A, Shah, Vijay H. , Singal, Ashwani K., Dunn, Winston, Kamath, Patrick S., Loomba, R, Arrese, Marco, Bataller, Ramon, Diaz, Luis Antonio, Arab, Juan Pablo, Elfeki, Mohamed A. , Perez, María I , Idalsoaga, Francisco , Ayala-Valverde, María , Ramirez-Cadiz, Carolina , Jalal, Prasun K , Ibrahim, Mohamad A , Elfeki, Mohamed A , Roblero, Juan P , Simian, Daniela , Velarde-Ruiz Velasco, José Antonio , Cordova-Gallardo, Jacqueline , Higuera-De La Tijera, Fatima , Silva, Rita , Fontani, Guilherme M , Bessone, Fernando , Mendizabal, Manuel , Marciano, Sebastián , Gomez-Perdiguero, Gonzalo , Montes, Pedro , Guerra Salazar, Patricia , Chacko, Kristina R , Simonetto, Douglas A , Sanyal, A J , Singal, Ashwani K , Dunn, Winston , Kamath, Patrick S , Loomba, Rohit , Bataller, Ramon A , Díaz, Luis A , Gormaz, Vania Cari, Téllez, Ignacio García, Idalsoaga, Francisco , Rhoads, Fisher, Ayala-Valverde, María , Jalal, Prasun K. , Roblero, Juan Pablo , Velasco, J.A. Velarde-Ruiz , Araújo, Roberta Chaves , Massote, Guilherme Fontanini, Pereira, Gustavo , Chacko, Kristina R. , Maiwall, Rakhi , Simonetto, Douglas A. , Sanyal, Arun J. , Singal, Ashwani K. , Dunn, Winston , Kamath, Patrick S. , Loomba, Rohit , Arrese, Marco , Díaz, Luis Antonio , Arab, Juan Pablo

Mayo Clinic

Hepatology | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001780 | PMID 42090455 Get It

Introduction: Although the role of cardiometabolic risk factors (CMRF) has been characterized in steatotic liver disease, their role in the severity of alcohol-associated hepatitis (AH) remains unclear. We aimed to evaluate the impact of CMRF on mortality. Methods: Multinational prospective cohort study (2015–2024) including hospitalized patients with severe AH across 32 centers in 14 countries. Diagnosis of AH was made using the NIAAA criteria. Analyses included adjusted competing-risk models by age, sex, ethnicity, history of cirrhosis, CMRF, corticosteroid use, MELD, and ACLF grade, with liver transplantation as a competing risk. Results: 936 participants were included; mean age 48±11.2 years, and 88.9% were male. At least one CMRF was present in 46.6%; median body mass index (BMI) was 24.2 kg/m 2 [IQR: 22.8–28.2], prevalence of diabetes 17.6%, hypertension 16.5%, and dyslipidemia 5.8%. Median MELD was 24.4 [19.3–31.4], 86.7% had severe AH, and 180-day survival was 72.9%. Survival did not differ by CMRF status (log-rank p =0.453). In adjusted competing-risk models, higher age (sHR 1.02; 95%CI:1.01–1.04), greater alcohol intake (per g/day; sHR 1.001; 95%CI:1.000–1.002), MELD (sHR 1.04; 95%CI:1.01–1.06), and ACLF grade 2–3 (sHR 2.34 and 4.34) predicted mortality. However, no individual CMRF independently increased mortality. A prespecified non-linear BMI analysis showed modestly lower mortality between 25–40 kg/m², with a higher risk above 40 kg/m². Conclusion: Among patients with severe AH, metabolic dysfunction was not associated with increased mortality. Although a higher BMI was associated with slightly lower mortality in AH, this may reflect better nutritional status rather than a true protective effect.
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
Silvey, Scott , Choudhury, Ashok , Kamath, Patrick S. , Wong, Florence , Hayes, P C, Seto, Wai‐Kay , Singhal, Garima, Jothimani, Dinesh , Asrani, Sumeet, Gadano, Adrián , Dinçer, Dinc , Adebayo, Daneille, Doyle, Adam, Debzi, Nabil , Shaw, Jawaid , Barutçu, Sezgin , Lah, Ponan Claude Regis, Duarte‐Rojo, Andrés , Turan, Dilara , Wang, Lei, Velazquez, René Malé, Aghayaeva, Sevda, Córdova-Gallardo, J, Xu, Bin, Gao, Haibing , Elangovan, Harendran, Fung, James, Rajorya, Neil, Wang, X I A O Y U, Katchman, Helena , Jiang, Yongfang, Thanapirom, Kessarin , Eapen, CE, Dhiman, Radha K. , Lu, Mingqin, Su, Minghua , Hueso, Sarai Gonzalez, Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping, MacQuillan, Gerry, Pereira, Gustavo, Reddy, K. Rajender , Topazian, Mark, Torre, A Ullate De La, Silva, Mario, Bush, Brian J., Bajaj, Jasmohan S. , Chaudhary, Ashok , Xie, Qing , Wong, Florence , Arora, Umang , Gadano, Adrian , Dincer, Dinc , Velarde-Ruiz Velasco, José Antonio , Kulkarni, Anand V , Shaw, Jawaid , Desalgn, Hailemicheal , Bettinger, Dominik , Regis Lah, Ponan Claude , Duarte-Rojo, Andres , Turan, Dilara , Zheng, Xin , Demirtas, Coskun , Liu, Chenghai , Cordova-Gallardo, Jacqueline , Nagral, Aabha , Gao, Haibing , Katchmann, Helena , Praharaj, Dibyalochan , Mahadeva, Sanjiv , Eapen, C E , Dhiman, Radha K , Lu, Mingqin , Arrese, Marco , Su, Minghua , Hueso, Sarai Gonzalez , Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping , Taneja, Sunil , Sonavane, Amey , Saraya, Anoop , Gofton, Cameron , Pereira, Gustavo , Rajender Reddy, K , Sarin, Shiv Kumar , Cao, Zhujun , Topazian, Mark D , Idilman, Ramazan , Torre, Aldo , George, Jacob , BUSH, BRIAN J. , Bajaj, Jasmohan S , Seto, Wai-Kay , Singhal, Garima, Asrani, Sumeet K. , Farias, Alberto Queiróz , Velasco, J.A. Velarde-Ruiz , Kulkarni, Anand V. , Desalegn, Hailemichael , Karasu, Zeki A. , Fung, James , Rajoriya, Neil , Zheng, Katina , Arrese, Marco , Zhu, Chuanwu , Taneja, Sunil , Aravinthan, Aloysious Dominic , MacQuillan, Gerry C., Idılman, Ramazan , George, Jacob , Alvares-da-Silva, Mario Reis

Mayo Clinic

American Journal of Gastroenterology | April 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004031 | PMID 42043180 Get It

INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
Drivers of Labor and Supply Cost Variation in Anterior Cruciate Ligament Reconstruction
Mun, Jeffrey , Dean, Michael C. , Gillinov, Stephen M. , Poutre, Rachel L. , Chenna, Srish S. , Allen, Brandon J. , Treloar, Joshua, Satalich, James R., Martin, Scott D., Mun, Jeffrey S , Treloar, Joshua A , Dean, M. Wingerchuk , Poutre, Rachel L. , Chenna, Srish S. , Etges, Ana Paula Beck da Silva , Satalich, James R. , Martin, Scott D.

Mayo Clinic

Journal of Bone and Joint Surgery | April 23, 2026 | Volume: 108 | Issue: 11 | Pages: 852-859

10.2106/jbjs.25.00667 | PMID 42024715 Get It

Background: Understanding drivers of supply and labor cost variation in orthopaedic surgery is crucial to provide value-based care. Time-driven activity-based costing (TDABC) is a more accurate methodology for capturing costs of care than traditional methods. Anterior cruciate ligament reconstruction (ACLR) is one of the most performed outpatient procedures within orthopaedic surgery. The purpose of this study was to characterize the cost composition of ACLR and identify factors that drive cost variation. Methods: Cost data for supplies and time-based personnel usage were extracted from electronic health records and were used to calculate costs using TDABC. TDABC methodology was applied to calculate the cost of personnel usage by multiplying the duration and associated cost per minute. Descriptive statistics and mixed-effects modeling were used to determine cost drivers. Results: This study included 861 patients who underwent ACLR at 8 hospitals. The mean patient age (and standard deviation) was 31.1 ± 11.6 years. Of the 861 patients, 350 were male and 511 were female; 85.6% of patients were White, 8.1% were Asian, and 3.4% were Black. There was 3.2-fold variation in supply costs ($2,950) and 1.6-fold variation in labor costs ($940) between the 10th and 90th percentiles. Overall, supply costs accounted for 58.2% of total costs, whereas labor costs comprised the remaining 41.8%. The intraoperative phase was the greatest generator of total cost (89.7%). After adjusting for surgeon and hospital variability, variation in total cost was most effectively explained by graft type, primary surgery status, and meniscal repair (conditional R 2 = 0.84; marginal R 2 = 0.27). On subanalysis, patients undergoing allograft ACLR had significantly higher total costs, implant costs, and age compared with those undergoing ACLR with any autograft type (all p < 0.01). Conclusions: The most notable drivers of labor and supply cost variation were graft type, surgeon, surgery center, primary surgery status, and concomitant meniscal repair. Understanding modifiable cost drivers may aid health systems in designing value-based pathways, implant formularies, and surgeon education programs. Future studies may integrate cost with outcome measures for a more holistic view of value. Level of Evidence: Economic and Decision Analysis Level III . See Instructions for Authors for a complete description of levels of evidence.
Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
Dingli, Sarah , Rothweiler, Paul , Corraes, Andre De Menezes Silva, Atallah‐Yunes, Suheil Albert , Ansell, Stephen M. , Bennani, N Nora, Johnston, Patrick B., Khurana, Arushi , Paludo, Jonas, Bisneto, J. C. Villasboas, Wang, Y, Lin, Yi, Erdman, Arthur G. , Atallah-Yunes, Albert , Durani, Urshila , Wang, Yucai , Erdman, Arthur G , Dingli, David , Corraes, Andre De Menezes Silva , Bennani, N. Nora , Durani, Urshila , Johnston, Patrick B. , Paludo, Jonas , Bisneto, J.C.C. Villasboas, Lin, Yi, Dingli, David

Mayo Clinic

British Journal of Haematology | April 21, 2026 | Volume: 209 | Issue: 1 | Pages: 189-196

10.1111/bjh.70502 | PMID 42011548 Get It

Summary Chimeric antigen receptor T cells directed against CD‐19 are highly effective therapies for various subtypes of B‐cell non‐Hodgkin lymphoma (NHL). We have studied the impact of patient‐specific lymphocyte growth kinetics after lymphoid depletion chemotherapy on both long‐term outcomes and toxicity in patients with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). The growth of the lymphocyte populations early after chimeric antigen receptor T‐cell (CAR‐T) therapy is well described by an exponential function and the growth rate of the cells appears to be one of the most critical determinants of overall survival in these patients. The maximum lymphocyte peak and the area under curve for lymphocytes within the first 4 weeks after CAR‐T therapy had no impact on survival. Receiver operator characteristic analysis determined that a replication rate ≥0.3876/day is associated with superior rates of complete response and durable responses. This threshold is associated with higher grades of cytokine release syndrome and the need for tocilizumab. However, patients with this threshold have a median overall survival of 3.04 years compared to 1.035 years for patients with slower lymphocyte replication ( p = 0.0206). The major determinant of depth of response and durability of response to CAR‐T in NHL is the speed of lymphocyte expansion.
Plasma Aβ42/p-Tau217 ratio and p-Tau217 independently predict CSF-defined Alzheimer’s disease pathology in a Brazilian admixed cohort
Silva, Marjorie Cristina da Rocha, Aventurato, Ítalo Karmann , Santos, Luis Eduardo, Silva, Ananssa Maíra dos Santos, Pinheiro, Thaís Lopes, Fernandes, Gustavo Bruniera Peres , Felice, Fernanda Guarino De, Balthazar, Marcio L. F., Rizzi, Liara , Ribeiro, Isadora Cristina , Pinheiro, TC , Balthazar, Marcio Luiz Figueredo

Mayo Clinic

Frontiers in Aging Neuroscience | April 21, 2026 | Volume: 18 | Issue: No issue available | Pages: No page available

10.3389/fnagi.2026.1773606 | PMID 42095059 Get It

Introduction Blood-based biomarkers offer a promising, minimally invasive approach to Alzheimer’s disease (AD) diagnosis, yet validation in admixed populations remains limited. We investigated whether plasma biomarkers predict CSF-defined AD pathology in a Brazilian cohort. Methods Seventy-eight older adults [including individuals with mild cognitive impairment (MCI), subjective cognitive decline (SCD), and cognitively unimpaired controls] underwent cognitive testing, neuroimaging, and plasma biomarker assessment. CSF data were available for symptomatic participants (MCI and SCD; n = 61), and regression and ROC analyses were performed in the subset with both CSF and APOE genotyping data ( n = 53). Plasma Aβ42, p-Tau181, p-Tau217, t-Tau, and derived ratios were quantified. Multivariable logistic regression and ROC analyses evaluated prediction of abnormal CSF p-Tau181/Aβ42 and t-Tau/Aβ42, adjusting for age, sex, and APOE ε4 status. Results Approximately 25% of individuals with MCI exhibited abnormal CSF p-Tau181/Aβ42 and t-Tau/Aβ42 ratios. Moderate correlations were observed between plasma and CSF biomarkers (r &gt; 0.4), particularly for Aβ42/p-Tau217 and p-Tau217. In adjusted models, plasma p-Tau217 and the Aβ42/p-Tau217 ratio independently predicted abnormal CSF pathology. Each one standard deviation increase in p-Tau217 was associated with 3.53–4.83-fold higher odds of abnormal CSF ( p ≤ 0.003). In contrast, higher Aβ42/p-Tau217 ratios were associated with substantially lower odds of pathology, with each one standard deviation increase corresponding to a 91%–93% reduction in risk ( p ≤ 0.002). The ratio showed stronger associations than p-Tau217 alone. ROC analyses demonstrated good discrimination. For CSF p-Tau181/Aβ42, Aβ42/p-Tau217 achieved an AUC of 0.88 (83% sensitivity, 85% specificity), compared with 0.83 for p-Tau217. For CSF t-Tau/Aβ42, both biomarkers yielded AUCs of 0.89. Discussion Plasma Aβ42/p-Tau217 and p-Tau217 effectively identify CSF-defined AD pathology in an admixed cohort. While higher p-Tau217 levels were associated with increased odds of pathology, higher Aβ42/p-Tau217 ratios were associated with lower pathological burden and demonstrated stronger effect sizes, supporting the added value of combining amyloid and tau biomarkers. These findings provide initial evidence for local validation of blood-based AD biomarkers in Brazil.
Focused ultrasound thalamotomy for essential tremor in octogenarians
Santini, Veronica, Ranjan, Manish, Bhagwat, Aniruddha , Silva, Nicole, Roque, Daniel, Winston, Graham , Ungar, Lior, Fay‐Karmon, Tsvia , Rezai, Ali R. , Zibly, Zion , Panchawagh, Suhrud , Santini, Veronica, Ranjan, Manish , Krishna, Vibhor , Roque, Daniel , Damisah, Eyiyemisi C. , Kaplitt, Michael G.

Mayo Clinic

Journal of Neurosurgery | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2025.12.jns251973 | PMID 41996720 Get It

OBJECTIVE Essential tremor (ET) is common and disabling in older adults. Many patients aged ≥ 80 years are ineligible for deep brain stimulation due to medical comorbidities. Data on noninvasive alternatives, such as MR-guided high-intensity focused ultrasound (MRgHIFU), remain limited in this population. The aim of this study was to evaluate the safety and efficacy of unilateral MRgHIFU thalamotomy targeting the ventral intermediate nucleus (VIM) for the treatment of ET in patients ≥ 80 years of age. METHODS This retrospective multicenter cohort study included consecutive patients aged ≥ 80 years with medically refractory ET treated with unilateral MRgHIFU VIM thalamotomy between 2016 and 2023 at five academic neurosurgical centers. All patients met skull density ratio criteria and underwent standardized targeting. Clinical assessments were conducted at baseline, immediately posttreatment, and at the 3-month follow-up. The primary outcome was change in tremor severity assessed by using the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS). Secondary outcomes included the Clinical Rating Scale for Tremor (CRST) score, Dynamic Gait Index score, patient-reported tremor relief, and adverse events. RESULTS One hundred twenty-nine patients (76 male, mean age 84 years) were included. At 3 months, the mean TETRAS score improved by 9.2 points (p < 0.001). CRST scores also showed significant improvement. The mean patient-reported tremor relief was 81%. Adverse events were mild and transient, with a 1.6% rate of nonsurgical adverse events. Subgroup analysis comparing patients 80–84 years versus those ≥ 85 years of age showed no significant differences in treatment response. Gait outcomes improved modestly but were not significant in the age ≥ 85 years group. CONCLUSIONS Unilateral MRgHIFU thalamotomy is a safe and effective noninvasive treatment for ET in patients ≥ 80 years of age. It results in significant improvements in tremor and disability, with a low complication rate. These findings support its consideration for older patients who are ineligible for invasive procedures and highlight the importance of age-specific metrics in neuromodulation outcomes research.
Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort
Bajaj, Jasmohan S, Kamath, Patrick S, Wong, Florence, Xie, Qing, Topazian, Mark, Seto, Wai-Kay, Torre, Aldo, Hayes, PC, Silva, Mario, Bush, Brian J., Choudhury, Ashok, Investigators, On behalf of the EXPLANTORREDO-TAVR Registry, Fisseha, Henok , Fisseha, Henok , Bajaj, Jasmohan S. , Kamath, Patrick S. , Wong, Florence , Xie, Qing , Idılman, Ramazan , Seto, Wai‐Kay , George, Jacob , Alvares-da-Silva, Mario, BUSH, BRIAN J. , Silvey, Scott , Choudhury, Ashok

Mayo Clinic

Clinical and Molecular Hepatology | April 15, 2026 | Volume: 32 | Issue: 3 | Pages: 1321-1332

10.3350/cmh.2026.0228 | PMID 42120075 Get It

Background/Aims: Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting. Aim: Determine predictors of DROs in a global cirrhosis inpatient cohort focusing on preadmission rifaximin use.Methods: From the global CLEARED consortium, we focused on cirrhosis inpatients with infections on/during admission. Clinical/demographic/medication, especially rifaximin details were recorded. The primary outcome was DRO development. Multivariable regression for DRO including clinical, medications, and country income was performed.Results: 2,949 infected inpatients (55.3 years, 62.9% male) were included. 12.2% of all and 24.4% of culture-positive infections developed DROs; these patients had higher HE (39 vs. 31%, <i>P</i>=0.003), hepatorenal syndrome (25 vs. 19%, <i>P</i>=0.006), lactulose (55 vs. 47%, <i>P</i>=0.008) and rifaximin use (34 vs. 27%, <i>P</i>=0.006) on crude comparisons but country-income distributions were similar. 29.7% were on pre-admission rifaximin, mostly HE-related; they had more advanced cirrhosis and from low/low-middle-income countries. Daptomycin was used in 1.5%, linked with DROs (5.0 vs. 1.0%, <i>P</i><0.0001) without a difference in rifaximin use (1.4 vs.1.7%, <i>P</i>=0.61). On adjusted analysis, MELD-Na (1.03, 95% CI 1.02–1.04, <i>P</i><0.001) increased, whereas male sex (0.73, 95% CI 0.58–0.92, <i>P</i>=0.008) and hepatitis-B (0.65, 95% CI 0.45–0.92, <i>P</i>=0.020) decreased DRO. Rifaximin was not associated with DROs overall (OR 1.07, 95% CI 0.80–1.43, <i>P</i>=0.65) or within income strata (high: 1.07, 95% CI 0.59–1.92, <i>P</i>=0.82, upper-middle: 1.18, 95% CI 0.74–1.85, <i>P</i>=0.49, low/low-middle: 1.04, 95% CI 0.60–1.81, <i>P</i>=0.90) despite sensitivity analyses.Conclusions: In this large global cohort of hospitalized patients with cirrhosis and infections, 12% developed infections involving DROs. 30% had pre-admission rifaximin use which was not linked with daptomycin use or with DRO development on adjusted analysis overall or across country income groups.